Abstracts tagged "B cells"

Abstract Number: 814 • 2016 ACR/ARHP Annual Meeting
The Regulatory B Cells Ameliorate Skin Sclerosis, Lung Fibrosis, and Autoimmunity Via an Anti-Oxidative Effect in Systemic Sclerosis Model Mice
Ayumi Yoshizaki, Takemichi Fukasawa, Satoshi Ebata, Kouki Nakamura, Takashi Yamashita, Ryosuke Saigusa, Yohei Ichimura, Takehiro Takahashi, Takashi Taniguchi, Asano Yoshihide and Shinichi Sato, Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by vascular damage, excessive deposition of extracellular matrix, and fibrosis in the several organs, including…
Abstract Number: 1840 • 2016 ACR/ARHP Annual Meeting
A Dichotomy of Regulatory Immunome Is Related to Disease Activity in Juvenile Systemic Lupus Erythematosus
Joo Guan Yeo^1,2, Thaschawee Arkachaisri^1,3, Justin Hung Tiong Tan¹, Jing Yao Leong⁴, Lena Das¹, Loshinidevi D/O Thana Bathi², Phyllis Chen² and Salvatore Albani^3,4, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Singhealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ³Duke-National University of Singapore Medical School, Singapore, Singapore, ⁴SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: The pathogenesis of SLE involves disturbances to the homeostatic balance between the immune effector and regulatory system. The conventional mono-dimensional mechanistic interrogation of one…
Abstract Number: 2785 • 2016 ACR/ARHP Annual Meeting
Translatable in Vitro Immunocyte Functional Measures of CC-292 and CC-90008 Inhibitors of the Bruton’s Tyrosine Kinase (Btk)/Tec Family and the Pathology Observed in the MLR/Lpr Mouse Model of Systemic Lupus Erythematosus (SLE)
Garth Ringheim¹, Jolanta Kosek², Lori Capone³, Mary Adams^4,5, Eun Mi Hur⁴ and Peter H. Schafer⁵, ¹86 Morris Avenue, Celgene Corporation, Summit, NJ, ²Translational Development, Celgene Corporation, Summit, NJ, ³Celgene Corporation, Summit, NJ, ⁴Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: CC-292 and CC-90008 are covalent Btk/Tec family kinase inhibitors that block Btk activity by binding with high affinity to the adenosine triphosphate (ATP) binding…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 1103 • 2015 ACR/ARHP Annual Meeting
Phosphatidylserine Outer Layer Translocation Is Implicated in IL-10 Secretion By Human Regulatory B Cells
Charlotte Hua¹, Rachel Audo², Michael Hahne², Bernard Combe³, Jacques Morel³ and Claire I. Daien³, ¹Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²IGMM-CNRS UMR5535, Montpellier, France, ³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: B cells can have a negative regulatory role, mainly mediated by interleukin 10 (IL-10) and we recently showed that IL-10 producing B cells (B10…
Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting
B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson³ and Jeremy Sokolove⁴, ¹Rheumatology, University College London, London, United Kingdom, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
Abstract Number: 3157 • 2015 ACR/ARHP Annual Meeting
B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE
Chungwen Wei¹, Bridget Neary², Jamie Biear³, Jennifer Barnard^3,4, Michelle Petri⁵, Alex Rosenberg⁶, Jennifer H. Anolik⁷ and Ignacio Sanz¹, ¹Rheumatology, Emory University, Atlanta, GA, ²Emory University, Atlanta, GA, ³Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁶University of Rochester, Rochester, NY, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: B cell abnormalities in SLE are well-established contributors to disease pathogenesis. Perturbation of B cell homeostasis in SLE is often described separately for each…
Abstract Number: 1104 • 2015 ACR/ARHP Annual Meeting
Mouse B Cells Require Glucose and Free Fatty Acids As Carbon Sources for Cytokine and Chemokine Secretion
Doujiao Wu¹, Dongyue Huang², Edward Pearce¹ and Alfred Kim², ¹Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO, ²Rheumatology, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: B cells contribute to disease pathophysiology through several mechanisms, including cytokine and chemokine secretion. A wide variety of stimuli can activate B cells including…
Abstract Number: 1667 • 2015 ACR/ARHP Annual Meeting
Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Canestri, Clara Di Mario, Marcin Nowik and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for Rheumatoid Arthritis (RA) and it is a modifier of B cell subsets in vivo, inducing changes in…
Abstract Number: 1105 • 2015 ACR/ARHP Annual Meeting
The IgG/IgG4 mRNA Ratio By Quantitative PCR Accurately Diagnoses IgG4-Related Disease and Predicts Treatment Response
Lowiek Hubers¹, Marieke Doorenspleet², Paulus Klarenbeek³, Emma Culver⁴, Lucas Maillette de Buy Wenniger⁵, Roger Chapman⁴, Stan Van de Graaf⁶, Joanne Verheij⁷, Thomas Van Gulik⁸, Frank Baas⁹, Ellie Barnes⁴, Ulrich Beuers¹ and Niek De Vries³, ¹Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Translational Gastroenterology Unit and NDM Oxford University, Translational Gastroenterology Unit and NDM Oxford University, John Radcliffe Hospital/Oxford University, Oxford, United Kingdom, ⁵1Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research,, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Dept. of Pathology, Dept. of Pathology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁸Dept. of Surgery, Dept. of Surgery, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁹Dept. of Genome Analysis, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose : IgG4-associated cholangitis (IAC) and autoimmune pancreatitis (AIP) are major manifestations of IgG4-related disease (IRD). Misdiagnosis and inadequate treatment are common since IAC and…
Abstract Number: 1668 • 2015 ACR/ARHP Annual Meeting
Patterns of Relapse in the Rheumatoid Arthritis Cohort Treated with Rituximab at University College London
Elena Becerra, Geraldine Cambridge, Inmaculada de la Torre and Maria J. Leandro, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Patterns of relapse in the Rheumatoid Arthritis cohort treated with Rituximab at University College LondonBackground/Purpose: Two patterns of relapse were defined in the first studies…
Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…
Abstract Number: 1754 • 2015 ACR/ARHP Annual Meeting
BANK1 Controls the Development of SLE By Modulating TLR7 Signaling and Type I IFN-Induced Translation Initiation Pathway in B Cells
Ying-Yu Wu¹, Ramesh Kumar², Harini Bagavant¹ and Marta E. Alarcon Riquelme³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma Cty, OK, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK
Background/Purpose: BANK1 is a susceptibility gene for SLE, and we have shown that stimulation of TLR9 agonist leads to a reduction in the activation of…
Abstract Number: 1 • 2015 ACR/ARHP Annual Meeting
The Integrin Very Late Antigen-4 Plays a Key Role in the Recruitment of B Cells at the Inflammatory Foci
Estefanía Armas-González¹, Ana Díaz-Martín², María Jesús Domínguez-Luis³, María Teresa Arce-Franco² and Federico Díaz-González⁴, ¹Universidad de La Laguna, Pharmacology Department, Tenerife, Spain, ²Hospital Universitario de Canarias, Rheumatology Service, Tenerife, Spain, ³CIBICAN, Center of Biomedical Research of the Canary Islands, University of La Laguna, Tenerife, Spain, ⁴Investigation Unit, Sociedad Española de Reumatológía, Madrid, Spain
Background/Purpose: Experimental data suggest that B cells must migrate and accumulate into the synovial membrane to exert their pathogenic role in rheumatoid arthritis (RA). Leukocyte…
Abstract Number: 1108 • 2015 ACR/ARHP Annual Meeting
Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor
Simon Lumb¹, Sarah J. Fleischer², Capucine Daridon², Alison Maloney¹, Anthony Shock¹ and Thomas Dorner², ¹UCB Pharma, Slough, United Kingdom, ²Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), a Leibniz Institute, Berlin, Germany
Background/Purpose: Epratuzumab, a humanized monoclonal antibody targeting CD22, is currently in phase 3 clinical trials in patients with systemic lupus erythematosus (SLE). Previous work suggests…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].